Towards Healthcare

Computer-Aided Detection Companies Strategic Expansion Initiatives

Date : 05 December 2025

Which Top Companies Are Leading the Computer-Aided Detection (CAD) Market in 2025?

Computer Aided Detection Market Companies

  • DeepTek AI
  • Delft Imaging
  • VinBrain
  • Infervision
  • JLK Group
  • Qure.ai
  • Kromek Group
  • Dassault Systèmes
  • Align Technology, Inc.

Introduction

The computer-aided detection market is primarily driven by the rising prevalence of chronic disorders, such as cancer, musculoskeletal disorders, and infectious diseases. Healthcare professionals leverage advanced computer tools to enhance diagnostic accuracy and reduce false negative rates. Integrating artificial intelligence (AI) in computer-aided detection (CAD) automates image identification and disease classification, thereby highlighting potential abnormalities.

Market Growth

The global computer-aided detection market size is calculated at USD 985.58 million in 2025, grew to USD 1037.13 million in 2026, and is projected to reach around USD 1640.93 million by 2035. The market is expanding at a CAGR of 5.23% between 2026 and 2035.

Computer Aided Detection Market Trends and Growth (2026)

Top Companies & Their Offerings in the Computer-Aided Detection Market

1. Fujifilm Corporation (Tokyo, Japan)

  • Offering: Fujifilm Digital Mammography CAD

  • Revenue: JPY 3,195 billion (FY 2025)

2. Olympus Corporation (Tokyo, Japan)

  • Offering: ENDO-AID CADe

  • Revenue: JPY 997.3 billion (FY 2025)

3. Samsung Healthcare (South Korea)

  • Offering: Lunit AI solutions & Auto Lung Nodule Detection

  • Revenue: KRW 1,660.2 billion (Q3 2025)

4. Riverain Technologies (Ohio, United States)

  • Offering: Chest X-ray CAD

  • Revenue: Not disclosed

5. iCAD, Inc. (New Hampshire, United States)

  • Offering: ProFound AI Detection

  • Revenue: USD 9.8 million (Q4 2024)

Hologic, Inc.

Company Overview:

  • A global medical technology innovator primarily focused on women's health, offering detection, diagnostic, and surgical solutions.
  • CAD Focus: A market leader in Computer-Aided Detection systems for breast health, particularly Digital Breast Tomosynthesis (3D Mammography).

Corporate Information:

  • Headquarters: Marlborough, Massachusetts, U.S.
  • Year Founded: 1985
  • Ownership Type: Public (NASDAQ: HOLX), Awaiting Acquisition: Announced a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone and TPG for up to $$79$ per share.

History and Background:

  • Began with a focus on bone densitometry and rapidly expanded its portfolio through strategic acquisitions and internal innovation in the women's health diagnostic and surgical space.
  • Established leadership in mammography and breast imaging with the introduction of 3D mammography systems.

Key Milestones/Timeline:

  • November 2024: Launched the Envision Mammography Platform at RSNA, offering an advanced 3D mammogram with a fast scan time of 2.5 seconds.
  • July 2024: Completed the acquisition of Endomagnetics, expanding its localization and tracing product portfolio within Breast Health.
  • October 2025: Announced agreement to be acquired by Blackstone and TPG.

Business Overview:

  • Develops, manufactures, and supplies high-performance diagnostic and surgical products, with a core mission centered on The Science of Sure$^{text{textregistered}}$ to deliver certainty in healthcare.
  • FY 2025 Revenue (TTM as of 09/30/2025): $$4.1$ Billion (Source: PitchBook).

Business Segments/Divisions:

  • Diagnostics (Largest segment by revenue, $sim44$% of total sales in FY 2025): Molecular Diagnostics, Cytology, and Perinatal.
  • Breast Health ($sim38$% of total sales in FY 2025): Includes Mammography (2D and 3D systems with CAD/AI, Biopsy, and Breast Surgery solutions).
  • Surgical ($sim16$% of total sales in FY 2025): Minimally invasive gynecological surgery products.
  • Skeletal Health ($sim2$% of total sales in FY 2025).

Geographic Presence:

Global operations, with the U.S. accounting for the largest portion of revenue ($sim69%)$, followed by Europe ($ sim20%$)$, and Asia ($sim8%$).

Key Offerings (CAD/AI):

  • Genius AI$^{text{TM}}$ Detection: CAD software designed to support radiologists by improving the accuracy and consistency of breast cancer detection, optimized for 3D mammography (Digital Breast Tomosynthesis or DBT).
  • 3DQuorum$^{text{TM}}$ Technology: CAD feature that generates a synthesized 3D image, reducing the number of 3D slices needing review by radiologists.
  • Clarity HD High-Resolution Imaging.

End-Use Industries Served:

  • Hospitals and Healthcare Systems.
  • Diagnostic and Imaging Centers.
  • Physician’s Offices and Clinics.

Key Developments and Strategic Initiatives:

Mergers & Acquisitions:

  • July 2024: Acquired Endomagnetics to enhance its breast-conserving surgery portfolio.
  • September 2025: Made a Later Stage VC investment in Mercy BioAnalytics.
  • February 2024: Made a Later Stage VC investment in Whiterabbit.ai (AI breast imaging).

Partnerships & Collaborations

Continues collaboration with organizations like the WTA (Women’s Tennis Association) to promote women's health awareness.

Product Launches/Innovations:

November 2024: Launched the Envision Mammography Platform with a 2.5-second scan time for 3D mammograms.

Capacity Expansions/Investments:

Ongoing significant R&D investment, contributing to a $sim4.8%$ Compound Annual Growth Rate (CAGR) in total sales over the decade leading up to 2024.

Regulatory Approvals:

  • October 2025: Received FDA Clearance and CE Mark for automated molecular tests to detect common causes of infectious gastroenteritis, expanding its diagnostic assay menu.
  • November 2025: Introduced Digital Pathology capabilities with expanded CE Marking.
  • Distribution channel strategy: Direct sales organization and distribution partners globally.

Technological Capabilities/R&D Focus:

  • Core Technologies/Patents: Holds over 3,200 total patent documents (applications and grants). Focus on AI, 3D imaging, molecular diagnostics, and minimally invasive surgery.
  • Research & Development Infrastructure: Substantial commitment to R&D innovation across all business segments.
  • Innovation Focus Areas: AI-powered diagnostic tools to reduce reading times and improve accuracy; expansion of the molecular diagnostics assay menu on the Panther system; next-generation 3D breast imaging.

Competitive Positioning:

Strengths & Differentiators: Strong global installed base in breast health, robust recurring revenue from diagnostic assays, deep integration of proprietary AI (Genius AI) into its 3D mammography platform, and a comprehensive portfolio focused on women's health.

Market presence & ecosystem role: Leader in the global breast imaging market; its Panther molecular system is a core driver in the Diagnostics segment.

SWOT Analysis:

  • Strengths: Market leadership in breast CAD/3D Mammography; strong, diversified portfolio; high recurring revenue base; consistent long-term sales growth.
  • Weaknesses: High cost of advanced equipment potentially limiting adoption in some emerging markets; cybersecurity concerns with cloud-based AI.
  • Opportunities: Global market penetration for AI-driven 3D mammography; expansion of AI solutions into other imaging modalities (e.g., pathology); leveraging the large private equity investment from Blackstone and TPG to accelerate growth.
  • Threats: Intense competition from large imaging conglomerates (GE, Siemens, Philips) and niche AI startups; regulatory changes in global healthcare.

Recent News and Updates:

Press Releases:

  • October 21, 2025: Hologic to be Acquired by Blackstone and TPG for up to $$79$ per Share (Total value up to $$18.3$ billion).
  • November 03, 2025: Announced financial results for Q4 fiscal 2025, with revenue of $$1,049.5$ million, growing 6.2%.

Industry Recognitions/Awards:

Included in the Dow Jones Sustainability North America Composite Index in the past, reflecting strong ESG performance.

iCAD, Inc.

Company Overview:

  • A medical technology company specializing in AI-powered cancer detection and risk assessment solutions.
  • CAD Focus: A key specialized vendor offering high-performance, Artificial Intelligence (AI) and Computer-Aided Detection (CAD) systems, primarily for 2D and 3D mammography.

Corporate Information:

  • Headquarters: Nashua, New Hampshire, U.S.
  • Year Founded: 1984
  • Ownership Type: Public (NASDAQ: ICAD), Acquired: Announced acquisition by RadNet Inc. in July 2025.

History and Background:

  • Founded to provide image analysis and workflow solutions for early cancer detection.
  • Transitioned from being a pure CAD company to a leader in AI-driven breast health solutions, particularly with its flagship ProFound AI$^{text{textregistered}}$ platform.

Key Milestones/Timeline:

  • H1 2023: Completed Xoft divestiture to focus solely on the Detection business.
  • Q2 2024: Reported Total Annual Recurring Revenue (T-ARR) of $$9.2$ million.
  • July 2025: Acquired by RadNet Inc., a provider of diagnostic imaging services.

Business Overview:

  • Focuses exclusively on its Detection business segment, which provides image analysis and workflow solutions, leveraging deep learning AI for breast cancer detection and risk assessment.
  • Revenue (2024): Approximately $$19.6$ million (Source: GlobalData).

Business Segments/Divisions:

Detection: Includes AI-powered CAD and workflow solutions for breast and other cancers, utilizing the ProFound AI suite. (Post-2023 divestiture of the Xoft therapy business, this is the sole focus.)

Geographic Presence:

  • Markets products globally in over 50 countries through direct sales, OEM partners (e.g., GE HealthCare), distributors, and resellers.
  • Operates in the U.S. and key European markets (France, Belgium, Italy, Germany, Switzerland).

Key Offerings (CAD/AI):

ProFound Suite:

  • ProFound AI Detection: Deep learning CAD for 2D and 3D (DBT) mammography, designed to rapidly analyze images and provide key metrics to radiologists, reducing reading time by an estimated $sim50%$.
  • ProFound AI Risk: Provides personalized, short-term breast cancer risk assessment in real-time.
  • ProFound Density: Automated breast density assessment.

End-Use Industries Served:

  • Diagnostic and Breast Imaging Centers.
  • Hospitals and Healthcare Systems.
  • Teleradiology service providers.

Key Developments and Strategic Initiatives:

Mergers & Acquisitions:

July 2025: Acquired by RadNet Inc.

Partnerships & Collaborations:

  • Signed 20-year partnership with Google Health.
  • First AI solution to be offered in GE HealthCare's MyBreastAI Suite.
  • July 2024: Entered agreement with Windsong Radiology to implement AI-powered mammography.
  • April 2024: Entered agreement with Densitas Inc. for breast cancer screening.

Product Launches/Innovations:

Continued enhancement of the ProFound AI platform with new features like Heart Health applications (currently not available in all geographies).

Capacity Expansions/Investments:

Focusing on expanding its AI solutions via a strong direct and indirect channel strategy.

Regulatory Approvals:

  • ProFound AI Detection: FDA Cleared, CE Marked, and Health Canada Licensed.
  • ProFound AI Risk: CE Marked (MDD) and Health Canada Licensed.
  • Distribution channel strategy: Mix of direct sales, OEM partnerships (e.g., GE), distributors, and resellers.

Technological Capabilities/R&D Focus:

  • Core Technologies/Patents: Focus on AI-powered image analysis and workflow solutions; holds over 200 total patent documents.
  • Key Patent: System and method for assessing breast cancer risk using imagery.
  • Research & Development Infrastructure: Leveraging its partnership with Google Health for R&D. Trained its deep learning models on a global data set of over $6$ million diverse images from $100+$ global centers.
  • Innovation Focus Areas: AI-driven risk assessment (ProFound AI Risk) and expanding AI applications beyond breast cancer detection to include cardiovascular health.

Competitive Positioning:

  • Strengths & Differentiators: Specialized focus on high-performance breast CAD/AI, leading ProFound AI platform with proven clinical evidence (e.g., $23%$ relative increase in cancer detection without increasing recalls), strong OEM partnerships (GE), and a highly diversified training data set.
  • Market presence & ecosystem role: A specialized leader in the breast AI market, often integrated into the hardware of major imaging vendors.

SWOT Analysis:

  • Strengths: Deep specialization in AI breast detection, highly-rated flagship product (ProFound AI), strategic 20-year R&D partnership with Google Health, and significant recurring revenue growth (16% CAGR in T-ARR).
  • Weaknesses: Smaller company revenue and market capitalization compared to conglomerate competitors; heavy reliance on a single product suite (ProFound AI).
  • Opportunities: Expansion of AI risk assessment and density solutions; leveraging the financial and customer base of its new parent company, RadNet, Inc.; growth in the underpenetrated U.S. AI mammography market ($sim63%$ unpenetrated).
  • Threats: Competitive pressure from major imaging OEMs developing in-house AI solutions and other emerging AI startups; integration challenges post-acquisition.

Recent News and Updates:

Press Releases:

The latest focus is on the successful execution of the management-led transformation plan, leading to significantly reduced cash burn (Q2 2024).

Industry Recognitions/Awards:

Cited in multiple clinical studies for the performance of its ProFound AI platform, demonstrating enhanced clinical performance compared to other platforms.

Recent Developments in the Computer-Aided Detection Market

  • In June 2025, the World Health Organization (WHO) approved 6 new software products for use in the CAD of tuberculosis on chest X-rays during TB screening. The approval was made based on an independent evaluation by the Technical Advisory Group on Tuberculosis Diagnostics and Laboratory Strengthening. The WHO has recommended the use of CAD for TB screening since 2021.
  • In March 2025, Align Technology, Inc. announced the launch of Align X-ray Insights, a new software-based CADe solution, in the European Union countries and the UK. The platform leverages AI to automatically analyze 2D radiographs to diagnose dental and oral conditions, standardizing analysis, streamlining workflows, and improving patient engagement.

Partner with our experts to explore the Computer-Aided Detection Market at sales@towardshealthcare.com